- Home
- GHI vs NKTR Comparison
GHI vs NKTR Comparison
Compare GHI & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- NKTR
- Stock Information
- Founded
- GHI 1998
- NKTR 1990
- Country
- GHI United States
- NKTR United States
- Employees
- GHI N/A
- NKTR N/A
- Industry
- GHI Finance: Consumer Services
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- GHI Finance
- NKTR Health Care
- Exchange
- GHI Nasdaq
- NKTR Nasdaq
- Market Cap
- GHI 273.8M
- NKTR 247.9M
- IPO Year
- GHI N/A
- NKTR 1994
- Fundamental
- Price
- GHI $11.78
- NKTR $0.89
- Analyst Decision
- GHI Strong Buy
- NKTR Strong Buy
- Analyst Count
- GHI 4
- NKTR 5
- Target Price
- GHI $17.50
- NKTR $4.50
- AVG Volume (30 Days)
- GHI 134.3K
- NKTR 1.5M
- Earning Date
- GHI 02-20-2025
- NKTR 03-03-2025
- Dividend Yield
- GHI 12.51%
- NKTR N/A
- EPS Growth
- GHI N/A
- NKTR N/A
- EPS
- GHI 0.61
- NKTR N/A
- Revenue
- GHI $34,307,528.00
- NKTR $93,137,000.00
- Revenue This Year
- GHI N/A
- NKTR $12.85
- Revenue Next Year
- GHI $10.35
- NKTR N/A
- P/E Ratio
- GHI $19.29
- NKTR N/A
- Revenue Growth
- GHI 28.98
- NKTR 5.53
- 52 Week Low
- GHI $10.12
- NKTR $0.50
- 52 Week High
- GHI $17.24
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- GHI 59.55
- NKTR 38.67
- Support Level
- GHI $11.50
- NKTR $0.88
- Resistance Level
- GHI $11.80
- NKTR $1.25
- Average True Range (ATR)
- GHI 0.38
- NKTR 0.09
- MACD
- GHI 0.15
- NKTR -0.01
- Stochastic Oscillator
- GHI 90.71
- NKTR 5.79
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.